Adjusted EBITDA: ~$380K–$400K (for a passive investor)
Opportunity Overview:
Attractive, established outpatient pediatric and family medicine practice led by a Nurse Practitioner with a light medical director oversight requirement. The practice operates five days per week with consistent patient volume and a strong payer base, predominantly Medicaid, in the Atlanta metro area. This is a rare absentee-friendly healthcare cash flow business with real estate ownership included, ideal for a passive investor or strategic operator seeking an asset-backed recurring revenue business.
Historical Revenue Trend:
- 2019: $1.2M
- 2020: $0.9M
- 2021: $0.9M
- 2022: $1.1M
- 2023: $1.2M
- 2024: $1.1M
- 2025: $1.0M
Business Highlights:
- NP-led care model with owner as Medical Director (?5 hr/week)
- Stable weekday patient visits (30–35/day M/T/W/F; 15–20 Thursday)
- In-house billing with long-tenured staff and minimal day-to-day physician involvement needed
- Integrated EHR/practice management platform
- Affordable entry valuation relative to normalized earnings
- Clean and defined 4-week transition with seller support
- No history of malpractice claims, payer audits, or regulatory issues
Real Estate:
- Practice located in owner-occupied building
- Included in sale for $750,000 (in addition to $1,500,000)
- Eliminates lease risk and provides tangible asset backing
Payer Mix:
- Medicaid & Medicaid Managed Care ~85%
- Commercial ~7.5%
- Self-Pay/Other ~7.5%
Earnings & Normalization:
- 2024 Adjusted EBITDA (Including rent and MD replacement adjustments): ~$398,000
- 2025 Adjusted EBITDA (Including same adjustments): ~$379,000
- Adjustments include owner benefits, family expenses, rent normalization, and market medical director cost
Buyer Profile:
Well-suited for private investors seeking a low-touch, cash-flowing healthcare platform, NP groups, regional operators, or investors with access to healthcare lending (SBA). Seller financing flexibility available if SBA lender requires a small note.
Confidentiality:
Detailed information available following execution of a Confidentiality Agreement and buyer qualification.
